비교리스트

 카트 문의
시장보고서
상품코드
1659418

세계의 골수이형성증후군(MDS) 치료제 시장

Myelodysplastic Syndrome (MDS) Drugs
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 89 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 골수이형성증후군(MDS) 치료제 시장은 2030년까지 41억 달러에 달할 전망

2024년에 24억 달러로 추정되는 세계의 골수이형성증후군(MDS) 치료제 시장은 분석 기간인 2024-2030년에 CAGR 9.3%로 성장하며, 2030년에는 41억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 면역 조절약은 CAGR 9.5%를 기록하며, 분석 기간 종료시에는 27억 달러에 달할 것으로 예상됩니다. 하이포메틸화제 부문의 성장률은 분석 기간 중 CAGR 5.3%로 추정됩니다.

미국 시장은 6억 2,230만 달러로 추정, 중국은 CAGR 13.8%로 성장할 것으로 예측

미국의 골수이형성증후군(MDS) 치료제 시장은 2024년에는 6억 2,230만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 11억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 13.8%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 4.6%와 8.2%로 예측됩니다. 유럽에서는 독일이 CAGR 5.6%로 성장할 것으로 예측됩니다.

세계의 골수이형성증후군(MDS) 치료제 시장 - 주요 동향과 촉진요인 정리

골수이형성증후군(MDS) 치료제 시장은 어떻게 변화하고 있는가?

골수이형성증후군(MDS) 치료제 시장은 환자 수 증가, 인구 고령화, 치료 옵션의 발전 등을 배경으로 성장하고 있습니다. MDS는 혈액 세포와 골수의 기능 장애를 특징으로 하는 혈액 질환군으로 빈혈, 감염, 출혈을 유발하며, MDS의 표준 치료법은 증상을 완화하고, 질병의 진행을 늦추고, 환자의 삶의 질을 개선하는 것을 목표로 합니다. 여기에는 성장인자, 메틸화 억제제, 면역 억제 요법, 수혈과 같은 지지요법이 포함됩니다. 현재의 치료에도 불구하고 MDS의 복잡한 생물학에 효과적으로 대처할 수 있는 치료법에 대한 미충족 수요는 여전히 높습니다.

MDS 치료제 개발의 새로운 동향은?

MDS 치료의 최근 동향은 질병의 불균일성을 해결하기 위한 표적치료제와 병용요법의 개발이 포함됩니다. 아자시티딘, 데시타빈과 같은 하이포메틸화제가 MDS 치료의 주류를 이루고 있으며, 효능을 높이기 위해 다른 약제와의 병용요법이 연구되고 있습니다. 또한 히스톤 탈아세틸화효소 억제제나 면역조절제 등 새로운 약제군의 연구도 주목받고 있습니다. 분자진단학의 발달로 MDS의 아형을 보다 정확하게 분류할 수 있게 되어 환자의 예후를 개선하는 맞춤 치료법 개발이 용이해지고 있습니다.

성장을 주도하는 시장 세분화는?

하이포메틸화제는 MDS 관리에 있으며, 확고한 역할을 수행하므로 가장 큰 점유율을 차지하고 있지만, 성장인자 부문도 특히 이 질환에 수반되는 빈혈을 관리하는 데 있으며, 중요한 역할을 하고 있습니다. 치료 유형에는 지지요법, 저강도 요법, 고강도 요법이 있으며, 지지요법은 MDS 관리에서 중요한 역할을 계속하고 있습니다. 판매 채널별로는 병원 약국이 시장을 독점하고 있지만, MDS 치료의 복잡성으로 인해 전문 약국이 성장하고 있습니다. 북미는 MDS 발병률이 높고, 첨단화된 의료 서비스에 대한 접근성이 높아 여전히 가장 큰 시장으로 남아 있습니다.

골수이형성증후군(MDS) 치료제 시장의 성장을 이끄는 요인은?

골수이형성증후군 치료제 시장의 성장은 여러 요인, 특히 노년층의 발병률 증가와 치료 옵션의 발전 등 여러 요인에 의해 주도되고 있습니다. 표적치료제와 새로운 병용요법의 개발로 치료 환경이 개선되어 환자들에게 보다 효과적인 질병 관리를 제공합니다. 또한 진단 기술의 발전으로 MDS의 조기 발견과 분류가 용이해져 맞춤 치료 접근이 가능해졌습니다. 면역요법 및 신약의 가능성을 탐색하기 위해 진행 중인 연구와 임상시험도 시장 확대에 기여하고 있습니다. 연구기관과 제약사의 전략적 제휴는 기술 혁신의 속도를 가속화하고 이 분야의 성장을 주도하고 있습니다.

부문

치료 클래스(면역조절제, 하이포메틸화제, 기타 치료 클래스)

조사 대상 기업의 예(총 34건)

  • Amgen
  • BluePoint Laboratories
  • Celgene Corporation
  • Celgene Europe Limited
  • Johnson & Johnson
  • Lupin Ltd Corporation
  • Otsuka America Pharmaceutical Inc.
  • Reddy's Laboratories, Inc.
  • Sandoz
  • Shilpa Medicare Limited
  • Sun Pharmaceutical Industries Inc.
  • Takeda

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.03.07

Global Myelodysplastic Syndrome (MDS) Drugs Market to Reach US$4.1 Billion by 2030

The global market for Myelodysplastic Syndrome (MDS) Drugs estimated at US$2.4 Billion in the year 2024, is expected to reach US$4.1 Billion by 2030, growing at a CAGR of 9.3% over the analysis period 2024-2030. Immunomodulatory Drugs, one of the segments analyzed in the report, is expected to record a 9.5% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Hypomethylating Agents segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$622.3 Million While China is Forecast to Grow at 13.8% CAGR

The Myelodysplastic Syndrome (MDS) Drugs market in the U.S. is estimated at US$622.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 13.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 8.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.

Global Myelodysplastic Syndrome (MDS) Drugs Market - Key Trends and Drivers Summarized

How Is the Market for Myelodysplastic Syndrome (MDS) Drugs Changing?

The Myelodysplastic Syndrome (MDS) drugs market is evolving, driven by an increasing number of cases, aging populations, and advancements in treatment options. MDS is a group of hematologic conditions characterized by dysfunctional blood cells and bone marrow, leading to anemia, infection, and bleeding. The standard treatment approach for MDS aims to alleviate symptoms, slow the disease's progression, and improve the patient's quality of life. This includes the use of growth factors, hypomethylating agents, immunosuppressive therapy, and supportive care such as blood transfusions. Despite current treatments, there remains a significant unmet need for therapies that effectively address the complex biology of MDS.

What Are the Emerging Trends in MDS Drug Development?

Recent trends in MDS treatment include the development of targeted therapies and combination regimens that seek to address the heterogeneity of the disease. Hypomethylating agents, such as azacitidine and decitabine, have become the mainstay of MDS therapy, and ongoing research is investigating their use in combination with other agents to enhance efficacy. The exploration of new drug classes, including histone deacetylase inhibitors and immunomodulatory agents, is also gaining attention. Advances in molecular diagnostics are enabling more precise characterization of MDS subtypes, facilitating the development of personalized treatment approaches that could improve patient outcomes.

Which Market Segments Are Leading Growth?

Hypomethylating agents account for the largest share due to their established role in managing MDS, but the growth factor segment is also significant, especially for managing anemia associated with the disease. Treatment types include supportive care, low-intensity therapy, and high-intensity therapy, with supportive care continuing to play a crucial role in MDS management. By distribution channel, hospital pharmacies dominate the market, though specialty pharmacies are seeing growth due to the increasing complexity of MDS treatment. North America remains the largest market due to higher MDS incidence and access to advanced healthcare.

What Factors Are Driving the Growth in the Myelodysplastic Syndrome (MDS) Drugs Market?

The growth in the Myelodysplastic Syndrome drugs market is driven by several factors, including increasing incidence rates, especially among older populations, and advancements in treatment options. The development of targeted therapies and novel combinations is enhancing the therapeutic landscape, providing patients with more effective management of the disease. Furthermore, improved diagnostic techniques are facilitating earlier detection and better classification of MDS, enabling personalized treatment approaches. Ongoing research and clinical trials exploring the potential of immunotherapies and new drug classes are also contributing to the expansion of the market. Strategic collaborations between research institutions and pharmaceutical companies are accelerating the pace of innovation, driving growth in this field.

SCOPE OF STUDY:

The report analyzes the Myelodysplastic Syndrome (MDS) Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapeutic Class (Immunomodulatory Drugs, Hypomethylating Agents, Other Therapeutic Classes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Amgen
  • BluePoint Laboratories
  • Celgene Corporation
  • Celgene Europe Limited
  • Johnson & Johnson
  • Lupin Ltd Corporation
  • Otsuka America Pharmaceutical Inc.
  • Reddy's Laboratories, Inc.
  • Sandoz
  • Shilpa Medicare Limited
  • Sun Pharmaceutical Industries Inc.
  • Takeda

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Global Economic Update
    • Myelodysplastic Syndrome (MDS) Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Targeted and Disease-Modifying Therapies Spurs Growth in Myelodysplastic Syndrome Drugs Market
    • Technological Advancements in Hypomethylating Agents Strengthen Business Case for Adoption
    • Growing Focus on Early Detection and Risk Stratification Expands Addressable Market
    • Expansion of MDS Drugs in Hematology and Oncology Centers Fuels Market Growth
    • Increasing Adoption of Combination Therapies and Novel Chemotherapies Expands Market Opportunities
    • Technological Innovations in Epigenetic Modifiers and Immunomodulatory Drugs Propel Market Expansion
    • Rising Focus on Improving Survival Rates and Quality of Life Drives Demand for MDS Drugs
    • Growing Use of MDS Drugs in Stem Cell Transplantation and Supportive Care Expands Market Potential
    • Focus on Complying with FDA and EMA Approval Pathways Strengthens Market for MDS Drugs
    • Rising Adoption of Next-Generation Therapeutics in High-Risk MDS Expands Addressable Market
    • Technological Advancements in Precision Medicine and Biomarker-Driven Therapies Propel Market Growth
    • Increasing Focus on Managed Access Programs and Compassionate Use Drives Adoption
    • Expansion of MDS Drugs in Palliative Care and Symptom Management Expands Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Immunomodulatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Immunomodulatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Immunomodulatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Hypomethylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Hypomethylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Hypomethylating Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Other Therapeutic Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Myelodysplastic Syndrome (MDS) Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: USA 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: Canada 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • JAPAN
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: Japan 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • CHINA
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: China 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • EUROPE
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Europe 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Europe 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • FRANCE
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: France 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • GERMANY
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Germany 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Italy 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: UK 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Spain 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Russia 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Rest of Europe 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Asia-Pacific 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Australia 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • INDIA
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: India 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: South Korea 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Latin America 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Latin America 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Argentina 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Brazil 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Mexico 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of Latin America 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Middle East 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Middle East 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Iran 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Israel 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Saudi Arabia 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UAE 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Rest of Middle East 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030
  • AFRICA
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Africa 15-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2015, 2025 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제